PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Vockerodt, M.* ; Vrzalikova, K.* ; Ibrahim, M.* ; Nagy, E.* ; Margielewska, S.* ; Hollows, R.* ; Lupino, L.* ; Tooze, R.* ; Care, M.* ; Simmons, W.* ; Schrader, A.* ; Perry, T.* ; Abdullah, M.* ; Foster, S.* ; Reynolds, G.* ; Dowell, A.* ; Rudski, Z.* ; Krappmann, D. ; Kube, D.* ; Woodman, C.* ; Wei, W.* ; Taylor, G.* ; Murray, P.G.*

Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma.

J. Pathol. 248, 142-154 (2019)
Postprint Forschungsdaten DOI PMC
Open Access Green
The Epstein-Barr virus (EBV) is found almost exclusively in the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), yet its contribution to this tumour remains poorly understood. We have focused on the EBV-encoded latent membrane protein-1 (LMP1), a constitutively activated CD40 homologue expressed in almost all EBV-positive DLBCLs and which can disrupt germinal centre (GC) formation and drive lymphomagenesis in mice. Comparison of the transcriptional changes that follow LMP1 expression with those that follow transient CD40 signalling in human GC B cells enabled us to define pathogenic targets of LMP1 aberrantly expressed in ABC-DLBCL. These included the down-regulation of S1PR2, a sphingosine-1-phosphate (S1P) receptor that is transcriptionally down-regulated in ABC-DLBCL, and when genetically ablated leads to DLBCL in mice. Consistent with this, we found that LMP1-expressing primary ABC-DLBCLs were significantly more likely to lack S1PR2 expression than were LMP1-negative tumours. Furthermore, we showed that the down-regulation of S1PR2 by LMP1 drives a signalling loop leading to constitutive activation of the phosphatidylinositol-3-kinase (PI3-K) pathway. Finally, core LMP1-PI3-K targets were enriched for lymphoma-related transcription factors and genes associated with shorter overall survival in patients with ABC-DLBCL. Our data identify a novel function for LMP1 in aggressive DLBCL. Copyright (c) 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
5.942
1.487
3
5
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter S1p ; S1pr2 ; Ebv ; Lmp1 ; Cd40 ; Dlbcl; Latent Membrane Protein-1; Nf-kappa-b; Barr-virus Oncoprotein; Gene-expression; Hodgkin Lymphoma; Mutations; Survival; Establishment; Association; Rituximab
Sprache
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 0022-3417
e-ISSN 1096-9896
Zeitschrift Journal of Pathology, The
Quellenangaben Band: 248, Heft: 2, Seiten: 142-154 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Signaling and Translation (SAT)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-509800-002
DOI 10.1002/path.5237
WOS ID WOS:000467873200003
Scopus ID 85063274668
PubMed ID 30666658
Erfassungsdatum 2019-03-07
[➜Korrektur melden]